BMC Public Health

Table 3 Validation of Year 1 HPV Vaccination administrative vs community coverage survey

From: Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges

	Facility-based coverage			Community-based coverage
	Target (n)	Coverage (%)	95% CI	n	Coverage (%)	95% CI	p value
Zomba:
1 dose	1930	91.2	89.9–92.5	309	87.7	83.3–92.1	0.05
2 doses	1930	86.8	85.3–88.3	309	87.4	82.9–91.8	0.78
3 doses	1930	84.7	83.1–86.3	309	85.8	81.3–90.3	0.63
Rumphi
1 dose	4294	96.2	95.6–96.8	307	97.4	95.6–99.2	0.30
2 doses	4294	93.2	92.4–94.0	307	95.8	93.9–97.8	0.09
3 doses	4294	90.2	89.3–91.1	307	94.2^a	91.7–96.7	0.03
Both districts
1 dose	6224	94.6^a	94.0–95.2	616	92.6	89.9–95.3	0.03
2 doses	6224	91.2	90.5–91.5	616	91.6	89.0–94.2	0.77
3 doses	6224	88.5	87.7–89.3	616	90.0	87.2–92.7	0.29

CI confidence interval, % percentage, ^astatistically significant facility vs community based coverage

Back to article page

ISSN: 1471-2458

Contact us

Submission enquiries: bmcpublichealth@biomedcentral.com
General enquiries: ORSupport@springernature.com